報價延遲最少15分鐘:2025/07/20 13:10 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.14 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.85/-2.14
|
|
企業價值
14.23M
|
| 資產負債 |
|
每股賬面淨值
2.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.95M
|
|
每股收益
1.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 13:10 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program,HB-500, are being developed in partnership with Gilead. |
